Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Policy

Displaying 24 papers

Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence

Publication: Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.

3/2016

Tags: Advocacy, Editorials, Policy, TB Burden

Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance

Publication: Sismanidis C, Glaziou P, Bloss E, et. al. Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance. 2016 Mar.

3/2016

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB Drug Market, TB Market

"Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments

Publication: Sismanidis C, Glaziou P, Bloss E, et. al. "Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments. 2016 Mar

3/2016

Tags: Advocacy, Editorials, MDR-TB, Policy, TB Burden, TB Drug Market, TB Market

Grand Convergence: Aligning Technologies & Realities in Global Health

Publication: Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.

3/2016

Tags: Advocacy, Editorials, Policy, TB Burden

The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective

Publication: Scott C, Gardiner E, de Lucia A. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:17-22. doi: 10.5588/ijtld.15.0478.

12/2015

Tags: Advocacy, Childhood TB, Policy, Regimen Change, TB Burden, TB Drug Market, TB Market

From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations

Publication: Malhotra S, Ursu I, Ghoneim R, et. al. From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:32-8. doi: 10.5588/ijtld.15.0482.

12/2015

Tags: Childhood TB, Policy, Regimen Change, TB Drug Market, TB Market

Pediatric tuberculosis drug market: an insider perspective on challenges and solutions

Publication: Usherenko I, Basu Roy U, Mazlish S, et. al. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:23-31. doi: 10.5588/ijtld.15.0479.

12/2015

Tags: Advocacy, Childhood TB, Policy

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement

Publication: Nachman S, Ahmed A, Amanullah, et. al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9.

5/2015

Tags: Advocacy, Childhood TB, Clinical Development, Editorials, Policy, Trial Design

Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborations

Publication: Furtado T, Franzen S, van Loggerenberg F, et. al. Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborations. PLoS Negl Trop Dis. 2014 Nov 13;8

11/2014

Tags: Advocacy, Clinical Development, Editorials, Policy

The multi-step process of building TB/HIV collaboration in Cambodia

Publication: Eang MT, Vun MC, Eam KK, et. al. The multi-step process of building TB/HIV collaboration in Cambodia. Health Res Policy Syst. 2012 Oct 18;10:34. doi: 10.1186/1478-4505-10-34.

10/2012

Tags: Advocacy, Editorials, Policy, TB Market, TB-HIV

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

Publication: Lienhardt C, Raviglione M, Spigelman M, et. al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034.

3/2012

Tags: Advocacy, Childhood TB, Clinical Development, Drug Discovery, Drug-Sensitivity Testing, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Pharmacodynamics, Pharmacokinetics, Policy, Preclinical Models, Pretomanid/PA-824, Regimen Change, TB Market, TB-HIV, Trial Design

Moxifloxacin for tuberculosis

Publication: Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012 Mar;12(3):176-7; author reply 177-8. doi: 10.1016/S1473-3099(11)70351-6.

3/2012

Tags: Advocacy, Clinical Development, Drug-Sensitivity Testing, Editorials, MDR-TB, Moxifloxacin, Policy, Regimen Change

Implications of the current tuberculosis treatment landscape for future regimen change

Publication: Wells WA, Konduri N, Chen C, et.al. Implications of the current tuberculosis treatment landscape for future regimen change. Int J Tuberc Lung Dis. 2011 Jun;15(6):746-53. doi: 10.5588/ijtld.10.0094.

6/2011

Tags: Drug-Sensitivity Testing, HRZE, MDR-TB, Policy, Regimen Change, TB Market

Size and Usage Patterns of Private TB Drug Markets in the High Burden Countries

Publication: Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One. 2011 May 4;6(5):e18964. doi: 10.1371/journal.pone.0018964.

5/2011

Tags: Policy, TB Burden, TB Drug Market, TB Market

Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making

Publication: Wells WA, Brooks A. Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making. Health Res Policy Syst. 2011 Mar 31;9:15. doi: 10.1186/1478-4505-9-15.

3/2011

Tags: Advocacy, Policy, Regimen Change, TB Market

Tuberculosis regimen change in high-burden countries

Publication: Wells WA, Konduri N, Chen C, et.al. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis. 2010 Dec;14(12):1538-47.

12/2010

Tags: Advocacy, Editorials, Policy, Regimen Change, TB Market

Global tuberculosis drug development pipeline: the need and the reality

Publication: Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9.

5/2010

Tags: Advocacy, Bedaquiline (TMC-207), Biomarkers, Childhood TB, Clinical Development, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Policy, Pretomanid/PA-824, Rifapentine, Sutezolid, Trial Design

Tuberculosis drug development: Progress, challenges, and the road ahead

Publication: Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb). 2010 May;90(3):162-7. doi: 10.1016/j.tube.2010.03.003.

4/2010

Tags: Advocacy, Clinical Development, Editorials, Global Pipeline, MDR-TB, Policy

Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships

Publication: Brooks AD, Wells WA, McLean TD, et. al. Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships. 2010. Innovation Strategy Today 2010 Jan. 3:1-5.

1/2010

Tags: Advocacy, Policy, Regimen Change, TB Market

Assessment of global capacity to conduct tuberculosis drug development trials- do we have what it takes

Publication: van Niekerk C, Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes? Int J Tuberc Lung Dis. 2009 Nov;13(11):1367-72. http://www.ingentaconnect.com/content/iuatld/ijtld/2009/00000013/00000011/a

11/2009

Tags: Advocacy, Clinical Development, Policy

Pages